Filaminast
Filaminast is a phosphodiesterase 4 inhibitor that is primarily used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). It was developed by the pharmaceutical company GlaxoSmithKline and is also known by its trade name, SB 207499.
Mechanism of Action[edit]
Filaminast works by inhibiting the action of phosphodiesterase 4 (PDE4), an enzyme that breaks down cyclic adenosine monophosphate (cAMP) in the body. By preventing the breakdown of cAMP, Filaminast increases the levels of this molecule in the body. cAMP plays a crucial role in the regulation of inflammatory responses in the body, and increased levels of cAMP can help to reduce inflammation and improve lung function in patients with asthma and COPD.
Clinical Use[edit]
Filaminast is used in the treatment of asthma and COPD, two chronic respiratory conditions that are characterized by inflammation and narrowing of the airways. By increasing the levels of cAMP in the body, Filaminast can help to reduce inflammation and improve lung function in these patients.
Side Effects[edit]
Like all medications, Filaminast can cause side effects. The most common side effects of Filaminast include nausea, vomiting, and diarrhea. In rare cases, Filaminast can cause serious side effects such as irregular heartbeat, difficulty breathing, and severe allergic reactions.
Research and Development[edit]
Filaminast was developed by GlaxoSmithKline, a British multinational pharmaceutical company. It was first synthesized in the 1990s and has since been studied in numerous clinical trials for its potential use in the treatment of asthma and COPD.
See Also[edit]
